证券之星消息，截至2026年2月27日收盘，可孚医疗(301087)报收于57.75元，上涨3.11%，换手率 1.63%，成交量3.16万手，成交额1.81亿元。 2月27日的资金流向数据方面，主力资金净流入2289.02万元，占总成交额12.68%，游资资金净流出 1232.51万元，占总成交额6.82%，散户资金净流出1056.52万元，占总成交额5.85%。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近5日资金流向一览见下表： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元， ...

证券之星消息，截至2026年2月26日收盘，可孚医疗(301087)报收于56.01元，上涨0.81%，换手率 0.87%，成交量1.7万手，成交额9447.76万元。 2月26日的资金流向数据方面，主力资金净流入501.59万元，占总成交额5.31%，游资资金净流入377.1 万元，占总成交额3.99%，散户资金净流出878.68万元，占总成交额9.3%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为53.84。 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗 ...

可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为53.84。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 证券之星消息，截 ...

Summary of Conference Call on Healthcare Services and Pharmacy Sector Industry Overview - The focus is on the healthcare services and pharmacy sectors within the pharmaceutical industry, particularly consumer-oriented segments, which are currently viewed positively due to historical low valuations after a prolonged adjustment period [1][2]. Key Points and Arguments Healthcare Services - The healthcare services sector has experienced significant declines, with current valuations at historical lows, indicating a potential for recovery by 2026 [1]. - Specific companies highlighted for their optimistic 2026 guidance include Tongce Medical, Gushengtang, and Aier Eye Hospital, all expected to show double-digit growth [1][2]. - The recovery in the sector is anticipated to be driven by improvements in supply structure and consumer environment, leading to a business rebound [2]. - Aier Eye Hospital is introducing new consumer-oriented surgical procedures, which may increase average transaction values despite stable surgical volumes [2]. Market Trends - Data from October 2025 shows positive growth in outpatient services in cities like Chongqing and Tianjin, with increases of 5-6% and 13-14% respectively [3]. - The overall trend indicates a recovery in both service volume and pricing, particularly in consumer-oriented medical fields like ophthalmology [3][4]. AI Integration - AI is expected to empower healthcare service companies, with applications like Ant Group's AI health app showing significant user growth, indicating a new growth driver for leading healthcare service firms [4][5]. Pharmacy Sector - The pharmacy sector is experiencing notable improvements in performance since Q3 2025, with leading companies showing consistent same-store sales growth [6]. - The sector is supported by government policies aimed at increasing industry concentration and chain store rates, which are expected to drive medium-term performance [6][7]. - Companies like Yifeng Pharmacy and Dazhong Pharmacy are highlighted for their strong cash flow and dividend yields, with Dazhong reporting a 60% dividend payout ratio [6][7]. Online vs. Offline Dynamics - The online pharmacy market is growing rapidly, but it serves a different demographic compared to traditional pharmacies, which cater more to older consumers [7][8]. - The online pharmacy market is projected to grow significantly, driven by products like GLP-1, but the overall growth rate may stabilize as both online and offline markets adjust [9][10]. Regulatory Environment - Recent government policies emphasize enhancing pharmacy service capabilities and supporting prescription outsourcing, which could lead to increased revenue opportunities for pharmacies [13][14]. - The focus on compliance and competition is expected to benefit larger pharmacy chains with established networks and resources for mergers and acquisitions [17]. Home Medical Devices - The home medical device sector is poised for growth due to an aging population and increasing health awareness, with significant potential in health monitoring devices like blood pressure monitors and glucose meters [18][19]. - Companies such as Yuyue Medical and Sanofi are recommended for their strong growth prospects in this segment [21]. Conclusion - The healthcare services, pharmacy, and home medical device sectors are expected to experience a bottom reversal, driven by improving fundamentals and supportive government policies. Key players in these sectors are well-positioned to capitalize on these trends, making them attractive investment opportunities moving forward [1][21].

证券之星消息，截至2026年2月13日收盘，可孚医疗(301087)报收于56.25元，上涨0.54%，换手率 1.15%，成交量2.23万手，成交额1.26亿元。 2月13日的资金流向数据方面，主力资金净流入1115.3万元，占总成交额8.88%，游资资金净流入537.28 万元，占总成交额4.28%，散户资金净流出1652.59万元，占总成交额13.16%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有6家机构给出评级，买入评级5家，增持 ...

Core Insights - The trend of gifting health-related products, particularly home massage devices, is gaining popularity as health awareness increases among consumers [1][6]. Group 1: Market Trends - Home massage devices are becoming a new favorite for gifting during the Spring Festival, replacing traditional local specialties [2][3]. - Online platforms are the preferred choice for purchasing home massage devices, with a significant increase in the variety of products available [1][4]. - The number of stock-keeping units (SKUs) for home massage devices and fascia guns has increased by 80% compared to the previous year [4][6]. Group 2: Consumer Preferences - Consumers are increasingly interested in multifunctional products that combine various massage techniques, such as kneading and tapping [5][6]. - The demand for products that cater to a wide range of users, including office workers and the elderly, is rising [3][5]. - The convenience of using massage devices at home is a significant factor driving their popularity, especially among those with sedentary lifestyles [2][3]. Group 3: Product Features - New trends in home massage devices include the integration of multiple functions and the ability to use them in various settings, such as cars and airplanes [5][6]. - Products are increasingly designed to be rechargeable, enhancing their portability and usability [5][6]. - Health monitoring products, such as continuous glucose monitoring systems, are also gaining traction, reflecting a shift towards proactive health management [6][7]. Group 4: Sales Performance - Sales of home massage devices have shown a noticeable increase, with many consumers purchasing them as gifts [3][5]. - The popularity of traditional health products, such as heat packs and cupping tools, is also on the rise, indicating a broader trend towards home health solutions [7].

Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

医疗器械 渠道积淀筑底，自研驱动与战略拓展打开成长空间 可孚医疗（301087.SZ） 证券研究报告/公司深度报告 2026 年 02 月 11 日 | 评级： | 买入（首次） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | | | 营业收入（百万元） | 2,854 | 2,983 | 3,384 | 4,098 | 5,100 | | 分析师：祝嘉琦 | | 增长率 yoy% | -4% | 5% | 13% | 21% | 24% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | 254 | 312 | 359 | 436 | 551 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | -16% | 23% | 15% | 22% | 26% | | | | 每股收益（元） | 1.22 | 1.49 | 1.72 | 2.09 | ...

Core Viewpoint - Kefu Medical is transitioning from hardware manufacturing to an "AI + healthcare" strategy, focusing on intelligent health management systems and product innovation [2] Group 1: Stock Performance - Kefu Medical's stock price closed at 55.20 yuan on February 10, 2026, with a daily increase of 1.28% and a trading volume of 139 million yuan [1] - Institutional investors showed optimism with a net inflow of 10.61 million yuan, while retail investors experienced net outflows of 2.41 million yuan and 8.20 million yuan respectively [1] - Over the past five trading days, the stock has risen by 3.36%, but it has decreased by 6.91% over the last 20 days, indicating significant volatility [1] Group 2: Recent Developments - On February 5, 2026, Kefu Medical established the Kefu Artificial Intelligence Research Institute in Changsha, Hunan, marking a strategic upgrade towards AI and data capabilities [2] - The research institute will focus on medical large models and multi-modal data analysis, aiming to transition products from functional devices to intelligent health management terminals [2] - The company plans to release the internal large model version 1.0 this year, initially validating AI algorithms on new respiratory devices [2] Group 3: Financial Performance - Kefu Medical reported a revenue of 2.398 billion yuan for the first three quarters of 2025, a year-on-year increase of 6.63%, with a net profit of 260 million yuan, up 3.30% [3] - The third quarter saw a significant revenue increase of 30.72% year-on-year, reaching 902 million yuan, with net profit and net profit excluding non-recurring items growing by 38.68% and 62.68% respectively [3] - The company's debt ratio stands at 27.37%, with financial expenses recorded at -3.77 million yuan, indicating stable financial operations [3] Group 4: Institutional Insights - Recent market attention towards Kefu Medical has been moderate, with neutral sentiment, but frequent institutional research activity [4] - Ten institutions have set a consensus target price of 54.56 yuan, indicating a potential downside of 1.16% from the latest stock price of 55.39 yuan [4] - Over the past 90 days, five institutions have rated the stock as "buy" or "hold," reflecting confidence in its long-term growth potential, with projected net profit growth of 17.13% in 2025 and 26.37% in 2026 due to AI technology implementation and industry demand expansion [4]

Core Viewpoint - The stock of Kefu Medical (301087) has shown a positive performance with a closing price of 55.2 yuan, reflecting a 1.28% increase as of February 10, 2026, with significant trading activity and a notable net inflow of funds [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, representing a year-on-year increase of 6.63% [2] - The net profit attributable to shareholders reached 260 million yuan, up 3.3% year-on-year, while the net profit after deducting non-recurring items was 222 million yuan, reflecting a 1.46% increase [2] - In Q3 2025 alone, the company achieved a quarterly revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2] - The quarterly net profit attributable to shareholders was approximately 92.83 million yuan, which is a 38.68% increase year-on-year, and the net profit after deducting non-recurring items was about 85.80 million yuan, up 62.68% [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while maintaining a gross profit margin of 53.35% [2] Market Activity - On February 10, 2026, the stock experienced a trading volume of 25,100 hands and a total transaction amount of 139 million yuan [1] - The net inflow of main funds was 10.61 million yuan, accounting for 7.65% of the total transaction amount, while retail investors saw a net outflow of 8.20 million yuan, representing 5.91% of the total [1]